STUDY QUESTION Is it safe to perform controlled ovarian stimulation (COS) for fertility
preservation before starting anticancer therapies or ART after treatments in young breast …

Letrozole, an aromatase inhibitor that blocks estrogen synthesis by inhibiting the final step of
the estrogen biosynthetic pathway, has been used in the applications of a wide range of …

Background Healthy individuals and patients with cancer who are carriers of germline
pathogenic variants in the BRCA1/2 genes face multiple reproductive challenges that …

Objective To report two cases of fertility preservation in two transgender men without an
extended period of higher dose testosterone cessation. Design Chart abstraction was …

Fertility counseling should be offered to all individuals of young reproductive age early in the
patient's trajectory following a cancer diagnosis. Systemic cancer treatment and …

In patients with hormone receptor–positive early-stage breast cancer, adjuvant endocrine
treatment administered for up to 5-10 years after diagnosis significantly reduces the risk of …

Abstract STUDY QUESTION Does letrozole (LZ) co-treatment during ovarian stimulation with
gonadotropins for in IVF impact follicle recruitment, oocyte number and quality, embryo …

STUDY QUESTION Does ovarian stimulation with the addition of tamoxifen or letrozole
affect the number of cumulus-oocyte complexes (COCs) retrieved compared to standard …

Multiple sclerosis (MS) predominantly affects women of fertile age. Various aspects of MS
could impact on fertility, such as sexual dysfunction, endocrine alterations, autoimmune …

Recent advances in early detection and oncological therapies have ameliorated the survival
rate of young cancer patients. Yet, ovarian impairment induced by chemotherapy and …